SCHEMBL13627928

SCHEMBL13627928

O=C1/C(=N\O)c2cc(Cl)ccc2N1Cc1ccc(F)cc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH3A1 P30838 7/20 0.51
ALDH1A1 P00352 3/20 0.51
ALDH2 P05091 1/20 0.51
CA1 P00915 5/20 0.48
CA2 P00918 5/20 0.48
CA4 P22748 1/20 0.48
CA12 O43570 4/20 0.48
CA9 Q16790 4/20 0.48
UCHL3 P15374 1/20 0.47
UCHL1 P09936 1/20 0.47
LMNA P02545 2/20 0.47
CHRM5 P08912 1/20 0.46
HPGD P15428 1/20 0.46
UBE2N P61088 1/20 0.46
ATM Q13315 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CASP3 P42574 1/20 0.44
CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627874 0.92 ALDH3A1 (0.56) ALDH3A1ALDH1A1ALDH2CA1CA2
SCHEMBL13627937 0.91 CHRM5 (0.55) ALDH3A1ALDH1A1CA1CA2CA12
SCHEMBL13627932 0.88 CA1 (0.59) ALDH3A1ALDH1A1ALDH2CA1CA2
SCHEMBL13627931 0.87 CA1 (0.56) ALDH3A1ALDH1A1ALDH2CA1CA2
SCHEMBL13627927 0.87 ALDH3A1 (0.68) ALDH3A1ALDH1A1ALDH2CA1CA2
SCHEMBL13627901 0.86 ACHE (0.58) ALDH3A1ALDH1A1ALDH2CA1CA2
SCHEMBL13627888 0.86 APAF1 (0.60) ALDH3A1ALDH1A1ALDH2CA1CA2
SCHEMBL13627919 0.86 ACHE (0.53) ALDH3A1ALDH1A1CA1CA2CA12
SCHEMBL13627964 0.84 UCHL3 (0.53) ALDH3A1ALDH1A1ALDH2CA1CA2
SCHEMBL13627940 0.84 CHRM5 (0.51) ALDH3A1ALDH1A1CA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ALDH3A1 4247/4885ALDH1A1 4310/4885ALDH2 3451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.